PURPOSE: To evaluate the short-term functional and anatomic outcomes of @entity1 with persistent @entity1103 ( @entity1103 ) who were converted from bevacizumab and/or ranibizumab to aflibercept. DESIGN: Retrospective, interventional, noncomparative, consecutive case series. METHODS: Only eyes treated with at least 4 consecutive injections of ranibizumab/bevacizumab spaced 4-6  weeks apart prior to conversion and with at least 2 aflibercept injections afterward were considered for inclusion. Pertinent @entity1 demographic, examination, and treatment data were extracted from clinical charts and tabulated for analysis. RESULTS: Fifty eyes of 37 @entity1 were included. Eyes received a mean of 13.7 bevacizumab/ranibizumab injections prior to conversion, followed by 4.1 aflibercept injections over 4.6  months of subsequent follow-up. The mean logMAR visual acuity at the pre-switch visit was 0.60    0.43 (Snellen equivalent, 20/80). This improved to 0.55    0.48 (Snellen equivalent, 20/70) by the second visit after conversion, corresponding to a mean logMAR change of  -0.05    0.22 (P  = .12). The average central macular thickness from the pre-switch spectral-domain optical coherence tomography scan was 459.2    139.2   m. This significantly improved to 348.7    107.8   m by the second visit following conversion, reflecting a mean decrease of 112    141   m (P  < .0001). The mean intraocular pressure (IOP) recorded at the pre-switch visit was 15.1    3.3  mm Hg. At the second follow-up after converting to aflibercept, the IOP averaged 14.9    3.2  mm Hg, with a mean decrease of 0.2    3.0  mm Hg (P  = .63). CONCLUSIONS: Conversion to aflibercept for persistent @entity1103 resulted in significant anatomic improvements. While trends towards improved visual acuity and reduction in IOP were observed, these were not statistically significant.

Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1103 :: ('MESH:D008269', 'Disease') :: ['DME', 'diabetic macular edema']
@entity1103 :: (MESH:D008269,Disease) :: ['Diabetic Macular Edema']
